The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.05
Bid: 3.00
Ask: 3.10
Change: -0.05 (-1.61%)
Spread: 0.10 (3.333%)
Open: 3.10
High: 3.15
Low: 3.05
Prev. Close: 3.10
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

Wed, 13th Dec 2023 21:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

British Smaller Cos VCT PLC and VCT 2 - Leeds, England-based venture capital trusts - Confirm the addition of an over-allotment facility of GBP25 million to their subscription offer, following its launch in September. Add that they have received applications approaching GBP60 million so far, with the deadline for applications on March 28, 2024. Notes subscription was initially launched to raise GBP65 million.

----------

Frontier IP Group PLC - London-based intellectual property commercialisation company - Says portfolio company The Vaccine Group has appointed three animal health experts to its advisory board in order to support the scale-up of its herpesvirus-based platform. Says advisory board members are Merck & Co Inc's Christophe Barnier-Quer, as well as Johan Dreesen and Vaughn Kubiak. Neil Crabb, Frontier IP Chief Executive Officer, says: "I am delighted TVG has been able to form an advisory group of such good quality. It is a testament to the potential of the Company, its vaccine platform and pipeline, and I look forward to further developments as TVG's vaccines move towards scale up and full commercialisation."

----------

DeepVerge PLC - Dublin-based environmental and life sciences firm - Says it has made progress in its discussions with potential buyers of assets and intellectual property in its Modern Water and Labskin business units. Adds that it hopes to agree on a sale in January. Says, however, that even if both asset sets are sold, the sales will not be of enough value to avoid closure or administration of the two subsidiaries. Adds that it currently has debts of GBP300,000 and is unsure whether it will have the funds to pay these debts. Says shares expected to be cancelled on December 27.

----------

Good Energy Group PLC - Wiltshire, England-based supplier of 100% renewable power and an innovator in energy services - Says investee company Zapmap, an electric vehicle charge point mapping service, has expanded its market presence to mainland Europe. Says its mapping service is now available in France, Germany, Belgium, the Netherlands and Luxembourg. Says coming months will see Zapmap open features including EV route planning and charging payments. Good Energy Chief Executive Nigel Pocklington says: "Zapmap has made significant progress over the last year as it continues to broaden and deepen its market presence in the UK and now across Europe. It continues to track with the rapidly growing electric vehicle market, which has expanded by 40% in the UK last year with the share of electric vehicles new car registrations increasing in almost all EU countries."

----------

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Launches placing to raise GBP1.6 million, via the issue of 26.3 million shares at 6.0 pence each. Adds that it will also launch a retail offer at 6.0 pence per retail share. Says retail offer is only open to existing shareholders. Notes that certain directors will also subscribe for 500,000 shares at 6.0p each. Says it will raise GBP1.9 million in total, which will be used to integrate BioBank materials form its asset acquisition from Imagen, as well as research and development.

----------

Creo Medical Group PLC - Chepstow, Wales-based medical device company - Says it has completed the first procedure using Speedboat Ultraslim. Says the product was used for a lower Gastrointestinal tract procedure in the UK, with the first European procedure expected to follow shortly. Speedboat is used to treat gastrointestinal tract diseases, including bowel, stomach and oesophagus cancers. CEO Craig Gulliford comments: "This is yet another landmark moment for Creo Medical. We know what a difference this even smaller device will make in terms of broadening access to advanced energy in endoscopy for a wider pool of clinicians. Speedboat UltraSlim is compatible with all major endoscopes, meaning clinicians can bring advanced energy to their practices, allowing more patients to be treated endoscopically, which avoids surgery and the associated secondary costs and risks."

----------

Macfarlane Group PLC - Glasgow-based supplier of packaging materials - Promotes James Baird to senior independent director.

----------

Asia Strategic Holdings Ltd - Singapore-based developer and operator of consumer businesses located in emerging Asian economies - Agrees amended loan facility with Macan Pte Ltd, increasing its loan to USD4.5 million, from USD3.0 million. Adds that the increase is in order to support its expansion of its school network. Notes that it has agreed to extend the repayment date to December 31 2027. Macan is the largest shareholder of Asia Strategic, representing 32.4%, while Asia Strategic Chief Executive Enrico Cesenni holds 35.1% of the voting rights of Macan.

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.